Marco Cavaco

Dr. Marco Cavaco

Gulbenkian Institute for Molecular Medicine, Lisbon, Lisboa, Portugal
+1
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2021 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
BWBen Woods
Ben Woods
RSRúben D. M. Silva
Rúben D. M. Silva
CSClaudia Schmidt
Claudia Schmidt
DWDarren Wragg
Darren Wragg
Marco CavacoMarco Cavaco
Marco Cavaco
ACAngela Casini
Angela Casini

1 January 2017 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
Marco CavacoMarco Cavaco
Marco Cavaco
CPCarolina Pereira
Carolina Pereira
BKBruna Kreutzer
Bruna Kreutzer
Luis Pleno GouveiaLuis Pleno Gouveia
Luis Pleno Gouveia
BSBeatriz Silva-Lima
Beatriz Silva-Lima
MVMafalda Videira
Mafalda Videira

13 January 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Marco CavacoMarco Cavaco
Marco Cavaco
DGDiana Gaspar
Diana Gaspar
MCMiguel Castanho
Miguel Castanho
VNVera Neves
Vera Neves
The incidence of brain metastases (BM) in cancer patients is increasing. After diagnosis, overall survival (OS) is poor, elicited by the lack of an effective treatment. Monoclonal antibody (mAb)-based therapy has achieved remarkable success in treating both hematologic and non-central-nervous system (CNS) tumors due to their inherent targeting specificity. However, the use of mAbs in the treatment of CNS tumors is restricted by the blood–brain barrier (BBB) that hinders the delivery of either small-molecules drugs (sMDs) or therapeutic proteins (TPs). To overcome this limitation, active research is focused on the development of strategies to deliver TPs and increase their concentration in the brain. Yet, their molecular weight and hydrophilic nature turn this task into a challenge. The use of BBB peptide shuttles is an elegant strategy. They explore either receptor-mediated transcytosis (RMT) or adsorptive-mediated transcytosis (AMT) to cross the BBB. The latter is preferable since it avoids enzymatic degradation, receptor saturation, and competition with natural receptor substrates, which reduces adverse events. Therefore, the combination of mAbs properties (e.g., selectivity and long half-life) with BBB peptide shuttles (e.g., BBB translocation and delivery into the brain) turns the therapeutic conjugate in a valid approach to safely overcome the BBB and efficiently eliminate metastatic brain cells.

17 November 2020 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
Marco CavacoMarco Cavaco
Marco Cavaco
David AndreuDavid Andreu
David Andreu
MCMiguel Castanho
Miguel Castanho

24 December 2017 in Peptide Science
Verified
Journal Article
Closed access
PDF file
Marco CavacoMarco Cavaco
Marco Cavaco
MCMiguel Castanho
Miguel Castanho
VNVera Neves
Vera Neves

25 May 2021 in Bioconjugate Chemistry
Verified
Journal Article
Open access
DMDiogo A. Mendonça
Diogo A. Mendonça
MBMariët Bakker
Mariët Bakker
CCChristine Cruz-Oliveira
Christine Cruz-Oliveira
VNVera Neves
Vera Neves
M Angeles JimenezM Angeles Jimenez
M Angeles Jimenez
TTToni Todorovski
Toni Todorovski
Passing through the blood-brain barrier (BBB) to treat neurological conditions is one of the main hurdles in modern medicine. Many drugs with promising in vitro profiles become ineffective in vivo due to BBB restrictive permeability. In particular, this includes drugs such as antiviral porphyrins, with the ability to fight brain-resident viruses causing diseases such as HIV-associated neurocognitive disorders (HAND). In the last two decades, BBB shuttles, particularly peptide-based ones, have shown promise in carrying various payloads across the BBB. Thus, peptide–drug conjugates (PDCs) formed by covalent attachment of a BBB peptide shuttle and an antiviral drug may become key therapeutic tools in treating neurological disorders of viral origin. In this study, we have used various approaches (guanidinium, phosphonium, and carbodiimide-based couplings) for on-resin synthesis of new peptide–porphyrin conjugates (PPCs) with BBB-crossing and potential antiviral activity. After careful fine-tuning of the synthetic chemistry, DIC/oxyma has emerged as a preferred method, by which 14 different PPCs have been made and satisfactorily characterized. The PPCs are prepared by coupling a porphyrin carboxyl group to an amino group (either N-terminal or a Lys side chain) of the peptide shuttle and show effective in vitro BBB translocation ability, low cytotoxicity toward mouse brain endothelial cells, and low hemolytic activity. Three of the PPCs, MP-P5, P4-MP, and P4-L-MP, effectively inhibiting HIV infectivity in vitro, stand out as most promising. Their efficacy against other brain-targeting viruses (Dengue, Zika, and SARS-CoV-2) is currently under evaluation, with preliminary results confirming that PPCs are a promising strategy to treat viral brain infections.